Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism

Inclusion Criteria: * Patient is ≥ 19 years of age and male or female of any race/ethnicity. * Patient has signs or symptoms of acute DVT of the leg, acute PE or ATE; or had arterial intervention or surgery, such as endovascular abdominal aortic aneurysm repair preferably within 14 days prior to the planned study with \[18F\]GP1. * Patient has thromboembolic focus/foci confirmed by standard imaging modalities within 5 days prior to administration of \[18F\]GP1. * Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at time of screening. * Patient has clinical laboratory tests that are within the following ranges, determined within 7 days prior to administration of \[18F\]GP1: * White blood cell count ≥ 3.0 x 109/L; * Platelets ≥ 75.0 x 109/L; * ALT and AST ≤ 3.0 times upper limit of normal; * Bilirubin ≤ 1.5 times upper limit of normal; and * Serum creatinine ≤ 1.5 times upper limit of normal Exclusion Criteria: A patient will be excluded from this study if the patient does not fulfill the inclusion criteria, or if any of the following conditions are observed: * Patient or patient's legally acceptable representative does not provide written informed consent. * In case of acute DVT or PE, patient has a previous history of objectively diagnosed DVT or PE. * Patient had pretreatment with glycoprotein IIb/IIIa inhibitors within 15 days before the administration of \[18F\]GP1 * Chemotherapy is scheduled to given to patient before or within…